Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies.

Leukemia - 1 Jan 2022

Pepper Andrea G S, Zucchetto Antonella, Norris Kevin, Tissino Erika, Polesel Jerry, Soe Zarni, Allsup David, Hockaday Anna, Ow Pei Loo, Hillmen Peter, Rawstron Andrew, Catovsky Daniel, Bulian Pietro, Bomben Riccardo, Baird Duncan M, Fegan Christopher D, Gattei Valter, Pepper Chris

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclophosphamide
Share to Immunoglobulin Heavy Chains
Share to Immunoglobulin Variable Region

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Neoplasm Recurrence, Local

Share to Rituximab

Share to Telomere Homeostasis

Share to Vidarabine

Source

Open in PubMed Open full text

Identifiers

PMID: 34148055
DOI: 10.1038/s41375-021-01322-1
PMCID: PMC8727296

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies.PMID 34148055Read ↗

An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted TherapySemantic proximity Read ↗

CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia.Semantic proximity Read ↗

CD49d (ITGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status.Semantic proximity Read ↗

A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable diseaseSemantic proximity Read ↗

Short telomere length is associated with NOTCH1/SF3B1/TP53 aberrations and poor outcome in newly diagnosed chronic lymphocytic leukemia patients.Semantic proximity Read ↗

CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL.Semantic proximity Read ↗

Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia.Semantic proximity Read ↗

Optimizing frontline therapy of CLL based on clinical and biological factors.Semantic proximity Read ↗

Flow cytometry as a fast, cost-effective tool to assess IGHV mutational status in CLL.Semantic proximity Read ↗

FCR achieves long-term durable remissions in patients with IGHV-mutated CLL.Semantic proximity Read ↗

Fc receptor-like 2 (FCRL2) is a novel marker of low-risk CLL and refines prognostication based on IGHV mutation status.Semantic proximity Read ↗

Unmutated IGHV at diagnosis in patients with early stage CLL independently predicts for shorter follow-up time to first treatment (TTFT).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.